CA2738621C - Anthrax vaccine formulation and uses thereof - Google Patents

Anthrax vaccine formulation and uses thereof Download PDF

Info

Publication number
CA2738621C
CA2738621C CA2738621A CA2738621A CA2738621C CA 2738621 C CA2738621 C CA 2738621C CA 2738621 A CA2738621 A CA 2738621A CA 2738621 A CA2738621 A CA 2738621A CA 2738621 C CA2738621 C CA 2738621C
Authority
CA
Canada
Prior art keywords
phosphate
vaccine
anthrax
rpa
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2738621A
Other languages
English (en)
French (fr)
Other versions
CA2738621A1 (en
Inventor
Allan Watkinson
David Woodhouse
Robert Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Pharmathene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathene Inc filed Critical Pharmathene Inc
Publication of CA2738621A1 publication Critical patent/CA2738621A1/en
Application granted granted Critical
Publication of CA2738621C publication Critical patent/CA2738621C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2738621A 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof Active CA2738621C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19496708P 2008-10-02 2008-10-02
US61/194,967 2008-10-02
PCT/GB2009/051293 WO2010038076A1 (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Publications (2)

Publication Number Publication Date
CA2738621A1 CA2738621A1 (en) 2010-04-08
CA2738621C true CA2738621C (en) 2017-01-31

Family

ID=41292568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738621A Active CA2738621C (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Country Status (7)

Country Link
US (1) US9616117B2 (enExample)
EP (1) EP2344188B1 (enExample)
JP (1) JP5701760B2 (enExample)
AU (1) AU2009299615B2 (enExample)
CA (1) CA2738621C (enExample)
IL (1) IL212118A (enExample)
WO (1) WO2010038076A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738621C (en) 2008-10-02 2017-01-31 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
DE2632478A1 (de) 1975-07-23 1977-02-24 Coulter Electronics Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9618107D0 (en) 1996-08-30 1996-10-09 Secr Defence Vaccine production
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
CA2412197A1 (en) 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Powder compositions
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
WO2002100340A2 (en) 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0126266D0 (en) 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
MXPA04005538A (es) 2001-12-05 2005-06-08 Bhatnagar Rakesh Procedimiento para la preparacion de una vacuna no toxica contra el antrax.
WO2005123131A2 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
WO2004073735A1 (en) 2003-02-13 2004-09-02 Becton, Dickinson And Company Improved anthrax vaccines and delivery methods
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
KR20070057954A (ko) 2004-09-28 2007-06-07 알자 코포레이션 알룸-애주번트가 있는 면역 활성제의 안정화
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine
WO2008048344A2 (en) 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
WO2008079464A2 (en) 2006-09-08 2008-07-03 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
WO2008152654A1 (en) 2007-06-11 2008-12-18 Panacea Biotec Limited Anthrax fusion proteins, compositions and uses thereof
GB0801122D0 (en) * 2008-01-22 2008-02-27 Avecia Biolog Ltd Vaccine composition
CA2738621C (en) 2008-10-02 2017-01-31 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
CA2750321A1 (en) 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use

Also Published As

Publication number Publication date
JP5701760B2 (ja) 2015-04-15
US9616117B2 (en) 2017-04-11
WO2010038076A1 (en) 2010-04-08
IL212118A0 (en) 2011-07-31
US20110236425A1 (en) 2011-09-29
AU2009299615B2 (en) 2015-07-16
JP2012504589A (ja) 2012-02-23
EP2344188B1 (en) 2017-02-15
IL212118A (en) 2017-03-30
CA2738621A1 (en) 2010-04-08
EP2344188A1 (en) 2011-07-20
AU2009299615A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
TWI725973B (zh) 抗-ｃｇｒｐ抗體調配物
US7993648B2 (en) Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
JP7419070B2 (ja) 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP5745577B2 (ja) Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
US20160144023A1 (en) Dry solid aluminum adjuvant-containing vaccines and related methods thereof
WO2024067888A1 (zh) 一种预防或治疗水痘-带状疱疹病毒相关疾病的免疫组合物产品及其制备方法
AU2009299615B2 (en) Anthrax vaccine formulation and uses thereof
EP3558353A2 (en) New flavivirus vaccine
CN101478987A (zh) 含有单克隆抗独特型抗ca-125抗体和铝的药物组合物
WO2024148364A1 (en) Intertumoral and intratumoral delivery of cytokines using mesoporous silica rods as an immunomodulating system
RU2404794C2 (ru) Вагинальные суппозитории для лечения рака шейки матки
WO2024254149A2 (en) Virus-inspired compositions comprising virus-like proteins and checkpoint inhibitors, and methods of use thereof to treat cancer
HK40124168A (en) Methods of treating graves' disease using anti-fcrn antibodies
AU783081B2 (en) VP22 proteins and uses thereof
HK1245813B (en) Anti-cgrp antibody formulation
MX2013006501A (es) Vacuna fuertemente inactivada y todavia sumamente inmunogenica, y proceso para su fabricacion.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141009

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250403